Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Clareon Vivity/Vivity Toric

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* Understand and sign an approved Informed Consent form~* Previously implanted in both eyes with Clareon Vivity/Clareon Vivity Toric or Clareon Monofocal/Clareon Toric IOLs for at least 3 months and up to 6 months (90 to 180 days) after second eye implant.~* Other protocol-defined inclusion criteria may apply.~Key Exclusion Criteria:~* History of clinically significant ocular co-morbidities that would affect surgical outcomes based on investigator expert medical opinion.~* Subjects who were targeted to monovision defined as ≥ 1.50 Diopter (D) of anisometropia.~* Clinically significant PCO (posterior capsule opacification) affecting vision.~* Other protocol-defined exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Clareon Vivity/Vivity Toric (Type: EXPERIMENTAL): Previous implantation in both eyes with Clareon Vivity/Vivity Toric Extended Vision IOL (intraocular lens), with previous implantation defined as 90-180 days post second eye implantation
- Clareon Monofocal/Clareon Toric (Type: ACTIVE_COMPARATOR): Previous implantation in both eyes with Clareon Monofocal/Clareon Toric IOL (intraocular lens), with previous implantation defined as 90-180 days post second eye implantation

Based on this trial design, predict the completion outcome and termination type (if applicable).